Tag: approval of Stiolto Respimat

According to a recent article in Medscape, a new drug has cleared the final hurdles for FDA approval and is now available for treatment of patients with COPD: Stiolto Respimat (Boehringer Ingelheim). This once-daily oral inhalation spray combines tiotropium and olodaterol. Olodaterol is a long-acting beta-agonist that improves airflow within 5 minutes. Tiotropium is a long-acting anticolinergic. It should be noted that Stiolto Respimat does not